Wednesday’s Midday Stock Update: Clovis Oncology (CLVS), Veeva Systems (VEEV), Bluebird Bio (BLUE), Intercept Pharma (ICPT), Ziopharm Oncology (ZIOP)

So far Wednesday, November 27, NASDAQ is down -0.77% and the S&P is up 0.27%. Here are this morning’s most active stocks: Clovis Oncology (CLVSResearch Report), Veeva Systems (VEEVResearch Report), Bluebird Bio (BLUEResearch Report), Intercept Pharma (ICPTResearch Report) and Ziopharm Oncology (ZIOPResearch Report).

Clovis Oncology is up 10.18% in midday trading to $12.18. Shares opened today at $11.05. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a 3.35% potential upside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which implies a downside of 28% from current levels. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00.

Veeva Systems is down -7.94% in midday trading to $152.06. Shares opened today at $165.17. The company has a 52-week low of $79.26 and a 52-week high of $176.90. On the Street’s front, the average 12-month analyst price target for the stock is $178.45, marking a 8.04% potential upside from current levels. In a report released today, Morgan Stanley analyst Stan Zlotsky maintained a Hold rating on VEEV, with a price target of $160.00, which represents a slight downside potential from current levels. Separately, on the same day, Stephens Inc’s James Rutherford reiterated a Buy rating on the stock and has a price target of $185.00. In the last 30 days, insiders purchased $8,312 worth of VEEV shares. Over the last 3 months, the insider sentiment on Veeva Systems has been negative based on 134 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Bluebird Bio is up 6.1% in midday trading to $79.58. Shares opened today at $75.00. The company has a 52-week low of $71.42 and a 52-week high of $163.43. On the Street’s front, the average 12-month analyst price target for the stock is $105.71, marking a 40.95% potential upside from current levels. In a report released yesterday, Leerink analyst Mani Foroohar upgraded BLUE to Buy, with a price target of $119.00, which represents a potential upside of 59% from where the stock is currently trading. Separately, on November 19, Evercore ISI’s Joshua Schimmer downgraded the stock to Hold and has a price target of $86.00.

See today’s analyst top recommended stocks >>

Intercept Pharma is up 4.28% in midday trading to $106.00. Shares opened today at $101.65. The company has a 52-week low of $56.76 and a 52-week high of $131.87. On the Street’s front, the average 12-month analyst price target for the stock is $150.80, marking a 48.35% potential upside from current levels. In a report issued on November 25, Robert W. Baird analyst Brian Skorney reiterated a Buy rating on ICPT, with a price target of $227.00, which represents a potential upside of 123% from where the stock is currently trading. Separately, on the same day, Stifel Nicolaus’ Derek Archila maintained a Hold rating on the stock and has a price target of $102.00. In the last 30 days, insiders have sold $137.6K worth of ICPT shares. Over the last 3 months, the insider sentiment on Intercept Pharma has been positive based on 104 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Ziopharm Oncology is down -4.08% in midday trading to $5.17. Shares opened today at $5.39. The company has a 52-week low of $1.56 and a 52-week high of $7.25. On the Street’s front, the average 12-month analyst price target for the stock is $6.50, marking a 20.59% potential upside from current levels. In a report issued on November 8, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on ZIOP, with a price target of $6.50, which implies an upside of 21% from current levels.

Trending Stocks Based on Insider Activity >>